On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...

Florida Cancer Specialists & Research Institute, LLC (FCS) continues to expand the availability of life-changing and ...

Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.